Experimental HIV vaccine shows promise in early trial for people on ART
NCT ID NCT04985760
First seen Nov 06, 2025 · Last updated Apr 30, 2026 · Updated 34 times
Summary
This study tested an experimental HIV vaccine called Trimer 4571 in 32 adults with HIV who were already on suppressive antiretroviral therapy (ART). The goal was to see if the vaccine is safe and can help the immune system produce broadly neutralizing antibodies against HIV. Participants received either a low dose, a high dose, or a placebo. The study is complete, and results will show whether the vaccine is safe and stimulates an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIDS Clinical Trials Unit/The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.